Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China

Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China

Abstract Background To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg w...

Full description

Bibliographic Details
Main Authors: Xin Nie, Yulong Wang, Hong Yi, Yanbin Qiao
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Ophthalmology
Subjects:
Pathologic myopia
Choroidal neovascularization
Anti-VEGF therapy
Conbercept
Online Access:https://doi.org/10.1186/s12886-021-01877-8

Internet

https://doi.org/10.1186/s12886-021-01877-8

Similar Items